Radiopharm Theranostics Ltd
RADX, RDPTF · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D45Clinical-stage radiopharmaceutical developer with no product revenue, deep losses, and recurring financing needs.
Strengths
- Diversified licensed radiopharma pipeline with Lantheus partnership generating reimbursement revenue (revenue growth 95.6th pct)
- Refundable Australian R&D tax incentive (43.5%) cushions burn; current ratio 2.67
Risks
- History of operating losses, net margin -10.5x and ROE -0.89 with no path to near-term profitability
- Explicit need for additional capital and dilution risk; contingent-consideration license liabilities
Notable findings
- No interest coverageInterest coverage -584.59 (cannot cover interest)
- Net lossNet loss (net margin -1055.3%)
- Trial readout soonUpcoming trial readout ~2026-04-23 — PHASE2 · Brain Metastases From Solid Tumors
Key metrics
Gross margin
1.1%
Operating margin
-1050.6%
Net margin
-1055.3%
Return on equity
-89.4%
Return on assets
-44.3%
Interest coverage
-584.6×
Current ratio
2.7×
Tangible book value
$43M
Cash & investments
$29M
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07259213 ↗ | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC Castration-resistant Prostate Cancer | PHASE1/PHASE2 | Recruiting | 2028-11-30 |
| NCT06824155 ↗ | HEAT Trial (HER2 Antibody Therapy With Lutetium-177) HER2 Gene Mutation, Advanced Solid Tumors | EARLY_PHASE1 | Recruiting | 2027-12-01 |
| NCT06305962 ↗ | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors PDL1 Gene Mutation, Non Small Cell Lung Cancer | EARLY_PHASE1 | Recruiting | 2027-12-01 |
| NCT07189871 ↗ | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer | PHASE1/PHASE2 | Recruiting | 2027-12-01 |
| NCT05799274 ↗ | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors Healthy Volunteers, Pancreatic Ductal Adenocarcinoma | PHASE1 | Recruiting | 2026-05-01 |
| NCT06777433 ↗ | Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases Brain Metastases From Solid Tumors | PHASE2 | Active Not Recruiting | 2026-04-23 |
| NCT07272642 ↗ | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. Imaging, Colorectal Cancer | PHASE1 | Not Yet Recruiting | 2027-08-30 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-09-18 | 2025-06-30 | 0001213900-25-088699 ↗ |